USA-based Agilent Technologies (NYSE: A) has bought DNA sequencing firm Lasergen, paying $105 million for all outstanding shares in the company.
The move follows an initial investment in 2016, in which Agilent bought a 48% stake in the firm, with an option to acquire the rest.
The two firms have since been collaborating on building a sequencing workflow for clinical applications, using Lasergen’s Lightning Terminators chemistry, which they believe can provide faster, more accurate and less expensive genome sequencing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze